Point72 Asset Management
ORMP icon

Point72 Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Point72 Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.6K Buy
26,052
+610
+2% +$2.07K ﹤0.01% 3624
2025
Q4 		$72.5K Buy
+25,442
New +$65.6K ﹤0.01% 3764

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Point72 Asset Management's ORMP Position: Q1 2026 in Review

Point72 Asset Management increased its Oramed Pharmaceuticals (ORMP) stake by 2.4% in Q1 2026, buying an estimated $2.07K and bringing the position to 26,052 shares worth $88.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3624.

Point72 Asset Management first reported a position in ORMP in Q4 2025 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Point72 Asset Management held 26,052 shares of Oramed Pharmaceuticals worth $88.6K as of Q1 2026.
  • Point72 Asset Management bought 610 Oramed Pharmaceuticals shares in Q1 2026, an estimated $2.07K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3624 holding.
  • Point72 Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.